BIOMAT Database Logo BIOMAT Database Logo

Clinical experience with Fluosol-DA (20%) in the United States. 1985

K K Tremper, and E M Levine, and K Waxman

UI MeSH Term Description Entries
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D001802 Blood Substitutes Substances that are used in place of blood, for example, as an alternative to BLOOD TRANSFUSIONS after blood loss to restore BLOOD VOLUME and oxygen-carrying capacity to the blood circulation, or to perfuse isolated organs. Artificial Blood,Artificial Erythrocytes,Artificial Hemoglobin,Blood, Artificial,Erythrocyte Substitutes,Hemoglobin Substitutes,Red Cell Substitutes,Artificial Bloods,Artificial Erythrocyte,Artificial Hemoglobins,Blood Substitute,Bloods, Artificial,Cell Substitute, Red,Cell Substitutes, Red,Erythrocyte Substitute,Erythrocyte, Artificial,Erythrocytes, Artificial,Hemoglobin Substitute,Hemoglobin, Artificial,Hemoglobins, Artificial,Red Cell Substitute,Substitute, Blood,Substitute, Erythrocyte,Substitute, Hemoglobin,Substitute, Red Cell,Substitutes, Blood,Substitutes, Erythrocyte,Substitutes, Hemoglobin,Substitutes, Red Cell
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005466 Fluorocarbons Liquid perfluorinated carbon compounds which may or may not contain a hetero atom such as nitrogen, oxygen or sulfur, but do not contain another halogen or hydrogen atom. This concept includes fluorocarbon emulsions, and fluorocarbon blood substitutes. Perfluorinated and related polyfluorinated chemicals are referred to as PFAS and are defined as chemicals with at least two adjacent carbon atoms, where one carbon is fully fluorinated and the other is at least partially fluorinated. Fluorocarbon,Fluorocarbon Emulsion,Fluorocarbon Emulsions,Fluorotelomer Phosphate Esters,N-Alkyl Perfluoroalkyl Sulfonamido Carboxylates,PFAS Per- and Polyfluoroalkyl Substances,PFC Perfluorinated Chemicals,PFECAs Perfluoropolyether Carboxylic Acids,Per- and Polyfluoroalkyl Substances,Perfluoroalkane Sulfonamides,Perfluoroalkyl Carboxylates,Perfluoroalkyl Ether Carboxylates,Perfluoroalkyl Polyether Carboxylates,Perfluorocarbon,Perfluorocarbons,Perfluoropolyether Carboxylic Acids,Polyfluorocarbons,Fluorinated Telomer Alcohols,Fluoro-Telomer Alcohols,Polyfluorinated Telomer Alcohols,Telomer Fluorocarbons,Acids, Perfluoropolyether Carboxylic,Alcohols, Fluorinated Telomer,Alcohols, Fluoro-Telomer,Alcohols, Polyfluorinated Telomer,Carboxylates, Perfluoroalkyl,Carboxylates, Perfluoroalkyl Ether,Carboxylates, Perfluoroalkyl Polyether,Carboxylic Acids, Perfluoropolyether,Chemicals, PFC Perfluorinated,Emulsion, Fluorocarbon,Emulsions, Fluorocarbon,Esters, Fluorotelomer Phosphate,Ether Carboxylates, Perfluoroalkyl,Fluoro Telomer Alcohols,Fluorocarbons, Telomer,N Alkyl Perfluoroalkyl Sulfonamido Carboxylates,PFAS Per and Polyfluoroalkyl Substances,Per and Polyfluoroalkyl Substances,Perfluorinated Chemicals, PFC,Phosphate Esters, Fluorotelomer,Polyether Carboxylates, Perfluoroalkyl,Sulfonamides, Perfluoroalkane,Telomer Alcohols, Fluorinated,Telomer Alcohols, Polyfluorinated
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006895 Hydroxyethyl Starch Derivatives Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups. Hetastarch,Elohes,HAES-steril,Hemohes,Hespan,Hydroxyethyl Starch (130 KD-0.4 Substitution),Hydroxyethyl Starch 130-0.4,Hydroxyethylated Starches,Pentafraction,Pentaspan,Pentastarch,Plasmasteril,Starches, 2-Hydroxyethyl,2-Hydroxyethyl Starches,Derivatives, Hydroxyethyl Starch,Hydroxyethyl Starch 130 0.4,Starch Derivatives, Hydroxyethyl,Starches, 2 Hydroxyethyl,Starches, Hydroxyethylated
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

K K Tremper, and E M Levine, and K Waxman
Clinical experience with Fluosol-DA.
January 1983, Progress in clinical and biological research,
K K Tremper, and E M Levine, and K Waxman
Status of Fluosol-DA 20%.
June 1984, JAMA,
K K Tremper, and E M Levine, and K Waxman
[Clinical experience of hemodilution with fluosol-DA (author's transl)].
July 1981, Masui. The Japanese journal of anesthesiology,
K K Tremper, and E M Levine, and K Waxman
Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
January 1985, The Journal of cardiovascular surgery,
K K Tremper, and E M Levine, and K Waxman
U.S. clinical studies of the treatment of anemia with fluosol-DA 20%.
February 1984, Artificial organs,
K K Tremper, and E M Levine, and K Waxman
Resuscitation with Fluosol-DA 20%--tolerance to sepsis.
August 1986, The Journal of trauma,
K K Tremper, and E M Levine, and K Waxman
Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
January 1994, Artificial cells, blood substitutes, and immobilization biotechnology,
K K Tremper, and E M Levine, and K Waxman
Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%.
May 1984, Critical care medicine,
K K Tremper, and E M Levine, and K Waxman
Present status of clinical studies of Fluosol-DA (20%) in Japan.
January 1985, International anesthesiology clinics,
K K Tremper, and E M Levine, and K Waxman
Variation in tumor response to fluosol-DA (20%).
May 1989, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!